CPH Stock Overview
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
Cipher Pharmaceuticals Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$3.80|
|52 Week High||CA$3.81|
|52 Week Low||CA$1.54|
|1 Month Change||14.80%|
|3 Month Change||33.80%|
|1 Year Change||122.22%|
|3 Year Change||268.93%|
|5 Year Change||-19.32%|
|Change since IPO||2.70%|
Recent News & Updates
Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting StockMay 14
Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)May 18
Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen NextMar 20
Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%Jan 26
|CPH||CA Pharmaceuticals||CA Market|
Return vs Industry: CPH exceeded the Canadian Pharmaceuticals industry which returned -46.8% over the past year.
Return vs Market: CPH exceeded the Canadian Market which returned -3.4% over the past year.
|CPH Average Weekly Movement||4.5%|
|Pharmaceuticals Industry Average Movement||14.6%|
|Market Average Movement||9.9%|
|10% most volatile stocks in CA Market||18.4%|
|10% least volatile stocks in CA Market||4.1%|
Stable Share Price: CPH is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: CPH's weekly volatility (5%) has been stable over the past year.
About the Company
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company’s licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Cipher Pharmaceuticals Inc. Fundamentals Summary
|CPH fundamental statistics|
Is CPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CPH income statement (TTM)|
|Cost of Revenue||US$3.99m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.39|
|Net Profit Margin||45.18%|
How did CPH perform over the long term?See historical performance and comparison